We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Determines Esophageal Cancer Patient Treatment Options

By LabMedica International staff writers
Posted on 21 Oct 2014
Print article
Image: A fluorescent proximity ligation assay of protein-protein interactions (Photo courtesy of Abnova).
Image: A fluorescent proximity ligation assay of protein-protein interactions (Photo courtesy of Abnova).
A blood test that may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma has been introduced.

The blood test measures levels of two proteins found in the body, vascular endothelial growth factor-A (VEGF-A) and transforming growth factor-β1 (TGF-β1), indicate patients’ pathological response, and disease-free survival rates.

Scientists at the National Taiwan University Hospital (Taipei City, Taiwan) evaluated serum samples of 103 total patients with esophageal squamous cell carcinoma (ESCC) from 2004 to 2013. All patients received preoperative taxane-/5-fluorouracil-based chemotherapy (CCRT) and 40 gray (Gy) dose of radiation therapy prior to esophagectomy, the surgical removal of a part of the esophagus.

Serum samples were collected from patients before and within one month of completion of CCRT. The team used a proximity ligation assay (PLA) technique to screen for 15 serum biomarkers in 79 patients to evaluate the biomarkers’ association with pathological tumor regression on surgery and survival. The biomarkers significantly associated with pathological response (PathR) and survival rates were further analyzed by traditional enzyme-linked, immunosorbent assay (ELISA) to confirm initial biomarker findings by PLA in the total group of 103 patients.

The investigators found that patients with high VEGF-A were less likely to achieve complete tumor regression or a decrease in the size of a tumor or in the extent of cancer in the body, and that the survival rates were lower among patients who had high VEGF-A and high TGF-β1 levels before treatment. On ELISA, both pre- and post-CCRT VEGF-A levels were significantly correlated with PathR. Patients with pretreatment VEGF-A of less than 250 pg/mL showed a statistically significant pathologically complete response after CCRT (57.1%, or 20/35) compared to patients with VEGF-A of more than 250 pg/mL (26.5% or 18/68).

Jason Cheng, MD, the senior author of the study said, “Through the utilization of a specific blood test of serum biomarkers, we could potentially predict if a patient will have a favorable pathological response and outcome before radiotherapy. Treatment could be tailored for patients in order to achieve better outcomes and/or fewer side effects. Our study showed that the serum levels of VEGF-A and TGF-β1 were significant only before treatment. This would allow us to individualize the neoadjuvant treatment regimens based on the pretreatment serum levels of VEGF-A and TGF-β1.” The study was presented on September 14, 2014, at the American Society for Radiation Oncology’s (ASTRO’s) 56th Annual Meeting, held in San Francisco (CA, USA).

Related Links:

National Taiwan University Hospital 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.